Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Jun. 30, 2013

Quarterly Financial Information (Unaudited)

Schedule of Quarterly Financial Information (Unaudited)

	Fiscal Year 2013
	First Quarter Ended September 30, 2012			Second Quarter Ended December 31, 2012			Third Quarter Ended March 31, 2013			Fourth Quarter Ended June 30, 2013
	(In thousands, except per share data)
Revenues:
License and milestone fees	$	933		$	429		$	22,010		$	855
Research and development support		1,377			2,036			2,257			2,203
Clinical materials revenue		1,781			147			734			181
Royalty revenue		—			—			—			592
Total revenues		4,091			2,612			25,001			3,831
Expenses:
Research and development		23,700			21,656			21,318			20,399
General and administrative		5,639			5,464			4,995			5,373
Total expenses		29,339			27,120			26,313			25,772
Loss from operations		(25,248	)		(24,508	)		(1,312	)		(21,941	)
Other income (expense), net		56			115			(39	)		66
Net loss	$	(25,192	)	$	(24,393	)	$	(1,351	)	$	(21,875	)
Basic and diluted net loss per common share	$	(0.30	)	$	(0.29	)	$	(0.02	)	$	(0.26	)

	Fiscal Year 2012
	First Quarter Ended September 30, 2011			Second Quarter Ended December 31, 2011			Third Quarter Ended March 31, 2012			Fourth Quarter Ended June 30, 2012
	(In thousands, except per share data)
Revenues:
License and milestone fees	$	1,187		$	6,025		$	999		$	950
Research and development support		1,068			945			1,320			1,184
Clinical materials reimbursement		281			647			933			818
Total revenues		2,536			7,617			3,252			2,952
Expenses:
Research and development		17,161			15,559			16,933			19,539
General and administrative		4,841			4,834			5,021			5,726
Total expenses		22,002			20,393			21,954			25,265
Loss from operations		(19,466	)		(12,776	)		(18,702	)		(22,313	)
Other income, net		(17	)		23			33			(101	)
Net loss	$	(19,483	)	$	(12,753	)	$	(18,669	)	$	(22,414	)
Basic and diluted net loss per common share	$	(0.26	)	$	(0.17	)	$	(0.24	)	$	(0.29	)